Morgan Stanley Aurinia Pharmaceuticals Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Morgan Stanley holds 2,396,239 shares of AUPH stock, worth $29.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,396,239

Previous 2,367,762 1.2%

Holding current value

$29.5 Million

Previous $19 Million 6.62%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$7.2 - $8.64 $205,034 - $246,041	28,477 Added 1.2%	2,396,239 $20.3 Million
Q1 2025 May 15, 2025	BUY	$7.55 - $8.77 $5.46 Million - $6.34 Million	722,633 Added 43.93%	2,367,762 $19 Million
Q4 2024 Feb 14, 2025	BUY	$6.75 - $10.44 $1.18 Million - $1.82 Million	174,632 Added 11.88%	1,645,129 $14.8 Million
Q3 2024 May 14, 2025	BUY	$5.32 - $7.33 $2.57 Million - $3.54 Million	482,621 Added 48.85%	1,470,497 $10.8 Million
Q3 2024 Nov 14, 2024	BUY	$5.32 - $7.33 $2.57 Million - $3.54 Million	482,621 Added 48.85%	1,470,497 $10.8 Million
Q2 2024 May 14, 2025	SELL	$4.81 - $5.78 $3.16 Million - $3.8 Million	-657,253 Reduced 39.95%	987,876 $5.64 Million
Q2 2024 Oct 17, 2024	SELL	$4.81 - $5.78 $1.52 Million - $1.83 Million	-316,262 Reduced 24.25%	987,876 $5.64 Million
Q2 2024 Aug 14, 2024	SELL	$4.81 - $5.78 $1.52 Million - $1.83 Million	-316,262 Reduced 24.25%	987,876 $5.64 Million
Q1 2024 Oct 17, 2024	BUY	$4.93 - $9.31 $1.56 Million - $2.94 Million	316,262 Added 32.01%	1,304,138 $6.53 Million
Q1 2024 Aug 16, 2024	SELL	$4.93 - $9.31 $742,891 - $1.4 Million	-150,688 Reduced 10.36%	1,304,138 $6.53 Million
Q1 2024 May 15, 2024	SELL	$4.93 - $9.31 $742,891 - $1.4 Million	-150,688 Reduced 10.36%	1,304,138 $6.53 Million
Q4 2023 Aug 16, 2024	BUY	$7.13 - $9.49 $3.33 Million - $4.43 Million	466,950 Added 47.27%	1,454,826 $13.1 Million
Q4 2023 Feb 13, 2024	BUY	$7.13 - $9.49 $224,010 - $298,156	31,418 Added 2.21%	1,454,826 $13.1 Million
Q3 2023 Nov 15, 2023	SELL	$7.77 - $12.27 $2.04 Million - $3.22 Million	-262,378 Reduced 15.56%	1,423,408 $11.1 Million
Q2 2023 Aug 14, 2023	SELL	$8.96 - $11.69 $1.69 Million - $2.21 Million	-188,643 Reduced 10.06%	1,685,786 $16.3 Million
Q1 2023 May 15, 2023	BUY	$5.94 - $11.27 $2.29 Million - $4.35 Million	385,714 Added 25.91%	1,874,429 $20.5 Million
Q4 2022 Feb 14, 2023	BUY	$4.11 - $8.14 $89,129 - $176,524	21,686 Added 1.48%	1,488,715 $6.43 Million
Q3 2022 Nov 14, 2022	SELL	$6.66 - $12.39 $9.48 Million - $17.6 Million	-1,423,875 Reduced 49.25%	1,467,029 $11 Million
Q2 2022 Oct 27, 2022	SELL	$8.95 - $12.8 $1.36 Million - $1.94 Million	-151,776 Reduced 4.99%	2,890,904 $29.1 Million
Q2 2022 Aug 15, 2022	SELL	$8.95 - $12.8 $1.36 Million - $1.94 Million	-151,776 Reduced 4.99%	2,890,904 $29.1 Million
Q1 2022 Oct 27, 2022	BUY	$10.05 - $22.48 $1.53 Million - $3.41 Million	151,776 Added 5.25%	3,042,680 $37.7 Million
Q1 2022 May 13, 2022	SELL	$10.05 - $22.48 $17.2 Million - $38.4 Million	-1,708,039 Reduced 35.95%	3,042,680 $37.7 Million
Q4 2021 Feb 14, 2022	SELL	$17.78 - $33.08 $34.7 Million - $64.6 Million	-1,951,647 Reduced 29.12%	4,750,719 $109 Million
Q3 2021 Nov 15, 2021	BUY	$10.93 - $23.55 $73.3 Million - $158 Million	6,702,366 New	6,702,366 $148 Million

Others Institutions Holding AUPH

# of Institutions

243

Shares Held

62.4M

Call Options Held

1.03M

Put Options Held

666K

View Full List

About Aurinia Pharmaceuticals Inc.

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.75B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

More about AUPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account